Nexavar, Sorafenib

New Drug Approvals

Sorafenib3Dan.gifSorafenib2DACS.svg

SORAFENIB

N-[4-Chloro-3-(trifluoromethyl)phenyl]({4-[2-(N-methyl-carbamoyl)(4-pyridyloxy)]phenyl}amino)carboxamide ( BAY 439006)

(4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-methylpicolinamide)

Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar),[1] is a drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), and radioactive iodine resistant advanced thyroid carcinoma.

 

Sorafenib
Sorafenib2DACS.svg
Sorafenib3Dan.gif
Systematic (IUPAC) name
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]
phenoxy]-N-methyl-pyridine-2-carboxamide
Clinical data
Trade names Nexavar
AHFS/Drugs.com monograph
MedlinePlus a607051
Licence data EMA:Link, US FDA:link
Pregnancy cat. D (AU) D (US)
Legal status Prescription Only (S4)(AU)-only(CA)POM(UK)-only(US)
Routes Oral
Pharmacokinetic data
Bioavailability 38–49%
Protein binding 99.5%
Metabolism Hepaticoxidation and glucuronidation (CYP3A4 & UGT1A9-mediated)
Half-life 25–48 hours
Excretion Faeces (77%) and urine (19%)
Identifiers
CAS number

View original post 6,064 more words

Advertisements

About luciavazine

PHARMA PROFESSIONAL, ITALY
This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s